AT 06
Alternative Names: AT-06Latest Information Update: 04 Nov 2022
At a glance
- Originator Attralus
- Class Cell therapies; Gene therapies; Peptides; Recombinant fusion proteins
- Mechanism of Action Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyloidosis
Most Recent Events
- 17 Oct 2022 AT 06 is available for licensing as of 17 Oct 2022 (https://attralus.com/pipeline)
- 17 Oct 2022 Preclinical trials in Amyloidosis in USA (Parenteral) Before October 2022 (Attralus pipeline, October 2022)